Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model

Xenobiotica

Volumn 42, Issue 4, 2012, Pages 327-338

  Hobbs, Michael ^a   Parker, Connie ^a   Birch, Helen ^a   Kenworthy, Kathryn ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Bcrp; disposition; Mrp2; Oatp; perfused rat liver; pharmacokinetic model; Rosuvastatin

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN 2; RIFAMPICIN; RIFAMYCIN; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INHIBITION; DRUG TRANSPORT; FLOW RATE; LIVER; LIVER WEIGHT; MALE; NONHUMAN; RAT;

ACRIDINES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; ORGANIC ANION TRANSPORTERS; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES; TETRAHYDROISOQUINOLINES;

RATTUS;

EID: 84858381601     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.625452     Document Type: Article

References (33)

1. Abe K, Bridges AS, Yue W, Brouwer KL. (2008). In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors in sandwichcultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther 326:983-990.
2. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233-246. (Pubitemid 36677534)
3. Chen C, Lin J, Smolarek T, Tremaine L. (2007). P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 35:1725-1729. (Pubitemid 47481596)
4. Chen C, Stock JL, Liu X, Shi J, Van Deusen JW, DiMattia DA, Dullea RG, de Morais SM. (2008). Utility of a novel Oatp1b2 knockout mouse odel for evaluating the role of Oatp1b2 in the hepatic uptake of odel compounds. Drug Metab Dispos 36:1840-1845.
5. Crouse JR 3rd. (2008). An evaluation of rosuvastatin: pharmacokinetics, linical efficacy and tolerability. Expert Opin Drug etab Toxicol 4:287-304. (Pubitemid 351618775)
6. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. (2000). ifamycin SV and rifampicin exhibit differential inhibition of the epatic rat organic anion transporting polypeptides, Oatp1 and atp2. Hepatology 32:82-86. (Pubitemid 30432369)
7. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, hu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster A, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli W, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, amek-Gliszczynski MJ, Zhang L; International Transporter onsortium. (2010). Membrane transporters in drug development. at Rev Drug Discov 9:215-236.
8. Hagenbuch B, Meier PJ. (2004). Organic anion transporting olypeptides of the OATP/ SLC21 family: phylogenetic classification s OATP/ SLCO superfamily, new nomenclature and molecular/ unctional properties. Pflugers Arch 447:653-665. (Pubitemid 38241451)
9. Ho R, Wang Y, Leake B, Kim R. (2005). Multiple Oatp transporters ediate the cellular uptake of rosuvastatin. Clin Pharmacol Ther 64 February
10. o RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, im RB. (2006). Drug and bile acid transporters in rosuvastatin epatic uptake: function, expression, and pharmacogenetics. astroenterology 130:1793-1806.
11. Johnson BM, Zhang P, Schuetz JD, Brouwer KL. (2006). Characterization f transport protein expression in multidrug resistance-associated rotein (Mrp) 2-deficient rats. Drug Metab Dispos 34:556-562.
12. Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement f multiple transporters in the hepatobiliary transport of osuvastatin. Drug Metab Dispos 36:2014-2023.
13. Jemnitz K, Veres Z, Tugyi R, Vereczkey L. (2010). Biliary efflux ransporters involved in the clearance of rosuvastatin in sandwich ulture of primary rat hepatocytes. Toxicol In Vitro 24:605-610.
14. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, cheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, chinkel AH. (2002). The breast cancer resistance protein protects gainst a major chlorophyll-derived dietary phototoxin and rotoporphyria. Proc Natl Acad Sci USA 99:15649-15654. (Pubitemid 35403986)
15. Koeppel TA, Trauner M, Mennone A, Arrese M, Rios-Velez L, oyer JL. (1998). Role of glutathione in hepatic bile formation uring reperfusion after cold ischemia of the rat liver. J Hepatol 8:812-819. (Pubitemid 28223485)
16. Lam JL, Benet LZ. (2004). Hepatic microsome studies are insufficient o characterize in vivo hepatic metabolic clearance and metabolic rug-drug interactions: studies of digoxin metabolism in rimary rat hepatocytes versus microsomes. Drug Metab Dispos 2:1311-1316. (Pubitemid 39410918)
17. Lau YY, Wu CY, Okochi H, Benet LZ. (2004). Ex situ inhibition of epatic uptake and efflux significantly changes metabolism: epatic enzyme-transporter interplay. J Pharmacol Exp Ther 08:1040-1045. (Pubitemid 38263980)
18. Lau YY, Okochi H, Huang Y, Benet LZ. (2006). Multiple transporters ffect the disposition of atorvastatin and its two active hydroxyl etabolites: application of in vitro and ex situ systems. J Pharmacol xp Ther 316:762-771. (Pubitemid 43131004)
19. Li M, Yuan H, Li N, Song G, Zheng Y, Baratta M, Hua F, Thurston A, ang J, Lai Y. (2008). Identification of interspecies difference n efflux transporters of hepatocytes from dog, rat, monkey and uman. Eur J Pharm Sci 35:114-126.
20. Mao Q, Unadkat JD. (2005). Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133. (Pubitemid 41554295)
21. Meijer DK, Keulemans K, Mulder GJ. (1981). Isolated perfused rat livertechnique. Meth Enzymol 77:81-94.
22. Nezasa K, Takao A, Kimura K, Takaichi M, Inazawa K, Koike M. (2002). Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715-727. (Pubitemid 34984968)
23. Nezasa K, Higaki K, Takeuchi M, Nakano M, Koike M. (2003). Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379-388. (Pubitemid 36688114)
24. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M. (2002). Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 30:1158-1163. (Pubitemid 35265820)
25. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581. (Pubitemid 44908269)
26. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3- fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695-701. (Pubitemid 351468376)
27. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, Demby VE. (2009). An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino}methyl)-2-furyl]- 4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
28. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
29. Tirona R, Kim R. (2007). Organic anion-transporting poltpeptides. In: Drug Transporters 75-105, John Wiley Press
30. Van Waterschoot RA, Schinkel AH. (2011). A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 63:390-410.
31. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. (2009). Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
32. Weiss M, Hung DY, Poenicke K, Roberts MS. (2008). Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin. Eur J Pharm Sci 34:345-350.
33. Xiong H, Turner KC, Ward ES, Jansen PL, Brouwer KL. (2000). Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR(-) rats. J Pharmacol Exp Ther 295:512-518.